Introduction Two college stories have dominated campus news this fall, and both have been described as drug stories. They involve two different drugs. At the University of Mississippi, two students died on Sept. 21, 2026, in separate incidents. Kratom-derived pills were found at both scenes. Court records disclosed at an Oct. 9 federal hearing say...
Category: Health
Two Standards, One Border: The Vaccine Mandates That Stopped at the Rio Grande and at the Sanctuary State Line
For years, federal and state governments made jobs, military service, hospital work and school enrollment depend on vaccination. Those standards were never applied at the same strength to people entering between ports of entry, or to the jurisdictions that shelter them. Measles is now at a 35-year high, largely for reasons unrelated to the border....
Sued for Refusing an Abortion: The Surrogacy Clause Courts Won’t Enforce
A California couple is seeking at least $100,000 in damages from the woman who carried their son, on the theory that she breached their contract by declining to end the pregnancy. The clause they are suing over is one courts have long said cannot be enforced against a pregnant woman. What remains enforceable is the...
Fewer Kids, More Doubt: Northeast Football Programs Are Falling Below the Minimum
Port Jefferson High School was scheduled to open its 100th season of varsity football on Sept. 4 at Center Moriches. It will not play a down. The Royals finished the preseason with fewer than 12 players against a New York State minimum of 16, and Section XI Executive Director Tom Combs confirmed last week that...
From #21 to #3: How UnitedHealth Became the Biggest Winner of the Obamacare Era
When President Obama signed the Affordable Care Act into law in March 2010, the promise was affordable coverage for millions of Americans who lacked it. Sixteen years later, roughly 20 million more people do have insurance — but the clearest financial winner of the Obamacare era is not a patient, a hospital, or a taxpayer....
Iowa’s Rising Cancer Rates Collide With a Federal Order Shielding Glyphosate
Iowa now records the second-highest rate of new cancer diagnoses in the United States, trailing only Kentucky, and is one of only a handful of states where the rate is still climbing while the national rate falls. Much of the public debate has centered on the state’s intensive agriculture — and, increasingly, on glyphosate, the...
Crumbl’s 186-Gram ‘Dirty Soda’ Draws Scrutiny Over Sugar Content and Health Effects
Just as a wave of public-health pressure pushes American consumers and food companies toward lower-sugar, less-processed products, the dessert chain Crumbl Cookies has introduced a beverage moving in the opposite direction. A line of customizable “dirty sodas” sold by the chain has drawn public attention after one option was reported to contain 186 grams of...
FDA Gene-Editing Approvals Open a New Therapeutic Market as Companies Position and Regulators Weigh Safeguards
In December 2023, the U.S. Food and Drug Administration approved the first medicine built on CRISPR gene-editing technology. The decision did more than clear a single treatment. It established that a therapy which rewrites a patient’s DNA could move through the same regulatory pathway used for conventional drugs, and it signaled to investors, hospitals and...
New York Moves to Ban Potassium Bromate: What the Food Safety and Chemical Disclosure Act Means for Bakers, Manufacturers, and Consumers
New York is poised to become the second U.S. state, after California, to ban potassium bromate, red dye No. 3, and propylparaben from its food supply. The bill also closes a long-debated federal regulatory loophole — and could shape national manufacturing decisions well beyond the state line. On April 21, 2026, the New York State...
FDA Approves First Gene Therapy for Inherited Deafness: What Otarmeni Means for Patients, Medicine, and Deaf Culture
Introduction The U.S. Food and Drug Administration has approved the first FDA gene therapy for inherited deafness, a one-time treatment that restored measurable hearing in 80% of evaluable pediatric patients during clinical testing. The therapy, marketed as Otarmeni (lunsotogene parvec-cwha), targets a specific genetic cause of profound hearing loss tied to mutations in the OTOF...









